^
Association details:
| Biomarker: | EGFR mutation + LRP1B mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tecentriq (atezolizumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Distinct EGFR-driven Co-mutation Patterns Influence Atezolizumab Efficacy in NSCLC: Results from POPLAR and OAK Trials
Published date:
08/08/2023
Excerpt:
56 EGFR-mutated patients treated with atezolizumab were ultimately enrolled....Strikingly, EGFR&LRP1B CoMut patients exhibited higher objective response rate (ORR) than those with EGFR single mutation (SM) (28.57% vs 2.5%; P = 0.013) (Fig. 1B) and had significantly improved OS (median OS: not reached (NR) vs 7.82 months; P = 0.0377) (Fig. 1C) and PFS (median PFS: 5.55 months vs 1.94 months; P = 0.0097) (Fig. 1D).
